JB Chemicals & Pharmaceuticals Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-16
Stock price
₹2408.90
Market cap
38,687 Cr
Stock P/E
54.9
P/B
9.30
Dividend yield
0.8%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 896 Cr | 1,778 Cr | 2,622 Cr | 3,484 Cr | 1,004 Cr | 2,005 Cr | 963 Cr | 949 Cr | 1,094 Cr | 1,085 Cr | 1,065 Cr | 904 Cr |
| Operating expenses (approx.) | 658 Cr | 1,289 Cr | 1,903 Cr | 2,550 Cr | 718 Cr | 1,438 Cr | 701 Cr | 709 Cr | 779 Cr | 760 Cr | 751 Cr | 718 Cr |
| EBITDA | 238 Cr | 489 Cr | 719 Cr | 934 Cr | 286 Cr | 567 Cr | 263 Cr | 241 Cr | 315 Cr | 325 Cr | 314 Cr | 186 Cr |
| OPM % | 26.5% | 27.5% | 27.4% | 26.8% | 28.5% | 28.3% | 27.2% | 25.4% | 28.8% | 30.0% | 29.5% | 20.6% |
| Other income | 6 Cr | 13 Cr | 21 Cr | 37 Cr | 6 Cr | 16 Cr | 8 Cr | 14 Cr | 15 Cr | 15 Cr | 18 Cr | 12 Cr |
| Interest | 12 Cr | 22 Cr | 35 Cr | 44 Cr | 6 Cr | 8 Cr | 3 Cr | 1 Cr | 1 Cr | 1 Cr | 2 Cr | 1 Cr |
| Depreciation | 31 Cr | 64 Cr | 98 Cr | 138 Cr | 41 Cr | 83 Cr | 42 Cr | 46 Cr | 43 Cr | 44 Cr | 45 Cr | 50 Cr |
| Profit before tax | 194 Cr | 403 Cr | 587 Cr | 752 Cr | 240 Cr | 476 Cr | 218 Cr | 193 Cr | 272 Cr | 279 Cr | 267 Cr | 135 Cr |
| Tax % | 26.8% | 27.3% | 27.3% | 26.5% | 26.3% | 26.2% | 25.5% | 24.5% | 25.5% | 25.6% | 25.8% | 24.7% |
| Net profit | 142 Cr | 293 Cr | 426 Cr | 553 Cr | 177 Cr | 351 Cr | 162 Cr | 146 Cr | 202 Cr | 208 Cr | 198 Cr | 101 Cr |
| EPS (₹) | ₹18.39 | ₹18.92 | ₹27.53 | ₹35.66 | ₹11.39 | ₹22.64 | ₹10.46 | ₹9.36 | ₹12.99 | ₹13.29 | ₹12.63 | ₹6.35 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,643 Cr | 1,775 Cr | 2,043 Cr | 2,424 Cr | 3,149 Cr | 3,484 Cr | 3,918 Cr | 4,148 Cr | Sign in for TTM |
| Operating expenses (approx.) | 1,296 Cr | 1,356 Cr | 1,370 Cr | 1,842 Cr | 2,454 Cr | 2,587 Cr | 2,848 Cr | 3,007 Cr | Sign in for TTM |
| EBITDA | 347 Cr | 418 Cr | 673 Cr | 583 Cr | 696 Cr | 897 Cr | 1,070 Cr | 1,140 Cr | Sign in for TTM |
| OPM % | 21.1% | 23.6% | 32.9% | 24.0% | 22.1% | 25.7% | 27.3% | 27.5% | Sign in for TTM |
| Other income | 41 Cr | 51 Cr | 112 Cr | 39 Cr | 10 Cr | 37 Cr | 38 Cr | 60 Cr | Sign in for TTM |
| Interest | 4 Cr | 3 Cr | 7 Cr | 5 Cr | 36 Cr | 44 Cr | 12 Cr | 6 Cr | Sign in for TTM |
| Depreciation | 56 Cr | 66 Cr | 69 Cr | 73 Cr | 114 Cr | 138 Cr | 171 Cr | 183 Cr | Sign in for TTM |
| Profit before tax | 287 Cr | 349 Cr | 597 Cr | 505 Cr | 555 Cr | 752 Cr | 887 Cr | 952 Cr | Sign in for TTM |
| Tax % | 32.4% | 21.9% | 24.9% | 23.5% | 26.2% | 26.5% | 25.7% | 25.5% | Sign in for TTM |
| Net profit | 194 Cr | 272 Cr | 449 Cr | 386 Cr | 410 Cr | 553 Cr | 660 Cr | 709 Cr | Sign in for TTM |
| EPS (₹) | ₹23.54 | ₹34.20 | ₹57.96 | ₹49.86 | ₹53.00 | ₹35.66 | ₹42.45 | ₹45.16 | Sign in for TTM |
| Dividend payout % | — | — | — | 33.0% | 31.1% | 28.4% | 35.9% | 44.2% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 16 Cr | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 16 Cr | 16 Cr | 16 Cr |
| Reserves | 1,464 Cr | 1,420 Cr | 1,794 Cr | 2,119 Cr | 2,465 Cr | 2,908 Cr | 3,418 Cr | 4,143 Cr |
| Borrowings | 26 Cr | 32 Cr | 26 Cr | 45 Cr | 548 Cr | 357 Cr | 14 Cr | — |
| Other liabilities | 282 Cr | 334 Cr | 368 Cr | 389 Cr | 525 Cr | 714 Cr | 827 Cr | 809 Cr |
| Total liabilities | 1,792 Cr | 1,811 Cr | 2,200 Cr | 2,538 Cr | 3,554 Cr | 3,994 Cr | 4,274 Cr | 4,969 Cr |
| Fixed assets (net) | 543 Cr | 565 Cr | 542 Cr | 517 Cr | 532 Cr | 572 Cr | 610 Cr | 612 Cr |
| CWIP | 15 Cr | 16 Cr | 26 Cr | 14 Cr | 44 Cr | 63 Cr | 47 Cr | 61 Cr |
| Investments | 589 Cr | 536 Cr | 811 Cr | 146 Cr | 206 Cr | 388 Cr | 345 Cr | 765 Cr |
| Other assets | 987 Cr | 1,009 Cr | 1,460 Cr | 1,153 Cr | 1,556 Cr | 1,869 Cr | 1,935 Cr | 2,947 Cr |
| Total assets | 1,792 Cr | 1,811 Cr | 2,200 Cr | 2,538 Cr | 3,554 Cr | 3,994 Cr | 4,274 Cr | 4,969 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 170 Cr | 626 Cr | 801 Cr | 902 Cr | 704 Cr |
| Cash from investing | — | — | — | 2 Cr | -962 Cr | -404 Cr | -296 Cr | -586 Cr |
| Cash from financing | — | — | — | -138 Cr | 357 Cr | -385 Cr | -580 Cr | -123 Cr |
| Net cash flow | — | — | — | 34 Cr | 20 Cr | 11 Cr | 27 Cr | -5 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 107 Cr | 553 Cr | 674 Cr | 805 Cr | 704 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019Standalone only | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 19.7% | 24.5% | 33.4% | 23.9% | 19.2% | 23.1% | 26.1% | 23.0% |
| ROE % | 13.1% | 19.0% | 24.8% | 18.1% | 16.5% | -0.5% | 0.2% | 17.1% |
| Debtor days | 73 | 77 | 72 | 86 | 67 | 72 | — | — |
| Inventory days | 167 | 187 | 187 | 212 | 200 | 225 | 235 | 273 |
| Days payable | 62 | 90 | 110 | 119 | 111 | 159 | — | — |
| Cash conversion cycle | 178 | 174 | 149 | 179 | 156 | 137 | 235 | 273 |
| Debt / equity | 0.02 | 0.02 | 0.01 | 0.02 | 0.22 | 0.12 | 0.0040 | — |
| Current ratio | 4.32 | 3.44 | 4.74 | 3.32 | 2.80 | 2.15 | 3.06 | 4.98 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.68 | 0.30 | -0.09 | -0.10 |
Compare with peers
Loading peers…